ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB
CA245-0001
Phase 3 small_molecule active
Quick answer
ETOPOSIDE, Atigotatug + Nivolumab FDC, CARBOPLATIN, ATEZOLIZUMAB for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active